Albumin-binding GHRH analog
A long-acting GHRH analog with drug affinity complex (DAC) modification enabling weekly subcutaneous dosing through albumin binding.
Abstract
CJC-1295 with DAC (CJC-1295 long-acting; CAS 863288-34-0) is a modified GHRH 1-29 analog that incorporates a drug affinity complex (DAC) modification (a maleimidopropionyl-Lys side chain) which enables in vivo conjugation to circulating albumin through a covalent linkage with reduced cysteine 34. The albumin conjugation extends plasma half-life from minutes (for sermorelin) to approximately 6 to 8 days, enabling weekly subcutaneous dosing. The compound was developed by ConjuChem (Canada) and reached Phase 2 trials before being discontinued. The non-DAC version of CJC-1295 (without the albumin-binding modification) is the compound covered in our existing CJC-1295 nDAC monograph. The DAC version produces sustained mild GH and IGF-1 elevation rather than the pulsatile pattern of nDAC + GHRP combinations.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.